Adimmune Corporation
Research Adimmune Corporation (4142.TW) on Bullrun: market cap TWD 7.76B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4142.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 7.76B
- Financial periodQ2 2026
- RevenueTWD 66.76M
- Net income-TWD 160.23M
- Free cash flow-TWD 308.72M
- Gross margin-94.1%
Valuation Snapshot
latest market cap is TWD 7.76B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 7.76B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Adimmune Corporation
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adimmune Corporation's market cap?
Adimmune Corporation's market capitalization is TWD 7.76B.
What does Adimmune Corporation do?
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine.